Literature DB >> 1623868

Logistical problems in prehospital thrombolysis.

J Brügemann1, J van der Meer, P A de Graeff, L H Takens, K I Lie.   

Abstract

In this study we compared efficacy and safety of prehospital with in-hospital thrombolytic treatment with anistreplase in patients with acute myocardial infarction (AMI). Three-hundred and fifty patients with chest pain were screened for eligibility by the municipal ambulance staff and/or the general practitioner. Patients were included in the absence of contraindications and if the telephone-transmitted ECG showed AMI. In a 6 month period 16 patients (5%) were eligible, but only seven (2%) were randomized. Age over 70 years, duration of chest pain for longer than 4 h and logistic problems were the major factors responsible for the low inclusion rate. The mean time spent at home with and without the ECG procedure was 38 +/- 14 and 14 +/- 8 min, respectively (P less than 0.001). These results demonstrate that in a medium sized town prehospital delivery of intravenous thrombolytic therapy by paramedics and/or the general practitioner is not feasible, leads to unnecessary time delay and may therefore yield no clinical benefits.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623868     DOI: 10.1093/oxfordjournals.eurheartj.a060257

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

Review 1.  Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction.

Authors:  Michael McCaul; Andrit Lourens; Tamara Kredo
Journal:  Cochrane Database Syst Rev       Date:  2014-09-10

2.  Longer pre-hospital delay in acute myocardial infarction in women because of longer doctor decision time.

Authors:  J Bouma; J Broer; J Bleeker; E van Sonderen; B Meyboom-de Jong; M J DeJongste
Journal:  J Epidemiol Community Health       Date:  1999-08       Impact factor: 3.710

Review 3.  Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.

Authors:  K S Woo; H D White
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.